Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

Lei Lei Wu

News Reporter

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Trump’s HHS defends Biden-era stance on 340B rebate models

FDA staff return to White Oak campus en masse after Trump administration push

Incyte's stock sinks as pivotal skin disease data disappoint

Post-Hoc: Kennedy's anti-vaccine actions shouldn't surprise anyone

AstraZeneca taps Alteogen in deal worth more than $1.3B to make subcutaneous cancer drugs

George Church spinout developing genomically recoded organisms cuts most employees

Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug